141 related articles for article (PubMed ID: 3179933)
21. Nuclear findings of ovarian surface epithelial tumors.
Hirokawa M; Miyake Y; Shimizu M; Kanahara T; Manabe T; Fujiwara K; Kohno I
Diagn Cytopathol; 2000 Jan; 22(1):27-9. PubMed ID: 10613969
[TBL] [Abstract][Full Text] [Related]
22. Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies.
Charpin C; Bhan AK; Zurawski VR; Scully RE
Int J Gynecol Pathol; 1982; 1(3):231-45. PubMed ID: 6193072
[TBL] [Abstract][Full Text] [Related]
23. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma.
Loy TS; Calaluce RD; Keeney GL
Mod Pathol; 1996 Nov; 9(11):1040-4. PubMed ID: 8933513
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological Characteristics of Ovarian Metastasis from Colorectal and Pancreatobiliary Carcinomas Mimicking Primary Ovarian Mucinous Tumor.
Park CK; Kim HS
Anticancer Res; 2018 Sep; 38(9):5465-5473. PubMed ID: 30194204
[TBL] [Abstract][Full Text] [Related]
25. Comparison of glycoprotein expression between ovarian and colon adenocarcinomas.
Multhaupt HA; Arenas-Elliott CP; Warhol MJ
Arch Pathol Lab Med; 1999 Oct; 123(10):909-16. PubMed ID: 10506443
[TBL] [Abstract][Full Text] [Related]
26. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.
Kim MJ
J Korean Med Sci; 2005 Aug; 20(4):643-8. PubMed ID: 16100458
[TBL] [Abstract][Full Text] [Related]
27. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
28. CDX-2 immunostaining in primary and secondary ovarian carcinomas.
Tornillo L; Moch H; Diener PA; Lugli A; Singer G
J Clin Pathol; 2004 Jun; 57(6):641-3. PubMed ID: 15166272
[TBL] [Abstract][Full Text] [Related]
29. Carcinoembryonic antigen in human ovarian neoplasms.
Marchand A; Fenoglio CM; Pascal R; Richart RM; Bennett S
Cancer Res; 1975 Dec; 35(12):3807-10. PubMed ID: 1192434
[TBL] [Abstract][Full Text] [Related]
30. Ovarian carcinomas, including secondary tumors: diagnostically challenging areas.
Prat J
Mod Pathol; 2005 Feb; 18 Suppl 2():S99-111. PubMed ID: 15492758
[TBL] [Abstract][Full Text] [Related]
31. [An immunohistochemical study of intestinal mucinous antigens and CEA in ovarian epithelial tumors].
Liu A; Wang M; Li H
Zhonghua Bing Li Xue Za Zhi; 1995 Dec; 24(6):366-8. PubMed ID: 8732094
[TBL] [Abstract][Full Text] [Related]
32. [Immunohistochemical localization of estradiol in malignant epithelial tumors of the ovary].
Takamizawa M; Yaoi Y; Kumasaka T; Saito M
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Mar; 39(3):359-66. PubMed ID: 3559322
[TBL] [Abstract][Full Text] [Related]
33. Ovarian metastases of pancreaticobiliary tract adenocarcinomas: analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors.
Meriden Z; Yemelyanova AV; Vang R; Ronnett BM
Am J Surg Pathol; 2011 Feb; 35(2):276-88. PubMed ID: 21263249
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical study of cytokeratin 7 for the differential diagnosis of adenocarcinomas in the ovary.
Ueda G; Sawada M; Ogawa H; Tanizawa O; Tsujimoto M
Gynecol Oncol; 1993 Nov; 51(2):219-23. PubMed ID: 7506222
[TBL] [Abstract][Full Text] [Related]
35. Marker profile of mesothelial cells versus ovarian carcinoma cells.
van Niekerk CC; Jap PH; Thomas CM; Smeets DF; Ramaekers FC; Poels LG
Int J Cancer; 1989 Jun; 43(6):1065-71. PubMed ID: 2659540
[TBL] [Abstract][Full Text] [Related]
36. Utility of anti-carcinoembryonic antigen monoclonal antibodies for differentiating ovarian adenocarcinomas from gastrointestinal metastasis to the ovary.
Pavelic ZP; Pavelic L; Pavelic K; Peacock JS
Gynecol Oncol; 1991 Feb; 40(2):112-7. PubMed ID: 1707023
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
[TBL] [Abstract][Full Text] [Related]
38. SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases.
Schmoeckel E; Kirchner T; Mayr D
Pathol Res Pract; 2018 Mar; 214(3):426-430. PubMed ID: 29487003
[TBL] [Abstract][Full Text] [Related]
39. Multiple primary neoplasms. Ovarian carcinoid tumor, mucinous cystadenoma of low malignant potential tumor of left ovary, and adenocarcinoma of the colon.
Capaldo GR; Kunschner AJ; Amin RM
Arch Pathol Lab Med; 1996 Apr; 120(4):393-6. PubMed ID: 8619754
[TBL] [Abstract][Full Text] [Related]
40. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis.
Seidman JD; Kurman RJ; Ronnett BM
Am J Surg Pathol; 2003 Jul; 27(7):985-93. PubMed ID: 12826891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
